他汀类药物预防高血压患者心血管事件。ASCOT-LLA研究。 - Suppr | 超能文献

Statins to prevent cardiovascular events in hypertensive patients. The ASCOT-LLA study.

作者信息

Osende Julio I, Ruiz-Ortega Marta, Blanco-Colio Luis Miguel, Egido Jesus

出版信息

Nephrol Dial Transplant. 2004 Mar;19(3):528-31. doi: 10.1093/ndt/gfg538.

DOI:10.1093/ndt/gfg538

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Statins to prevent cardiovascular events in hypertensive patients. The ASCOT-LLA study.他汀类药物预防高血压患者心血管事件。ASCOT-LLA研究。

Nephrol Dial Transplant. 2004 Mar;19(3):528-31. doi: 10.1093/ndt/gfg538.

2

The Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm: extended observations 2 years after trial closure.盎格鲁-斯堪的纳维亚心脏结局试验降脂组：试验结束后2年的延长观察

Eur Heart J. 2008 Feb;29(4):499-508. doi: 10.1093/eurheartj/ehm583. Epub 2008 Jan 5.

3

Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension.盎格鲁-斯堪的纳维亚心脏结局试验中抗高血压治疗及阿托伐他汀的获益：降脂治疗组扩展研究

J Hypertens. 2009 May;27(5):947-54. doi: 10.1097/HJH.0b013e328326cb1a.

4

Different time course for prevention of coronary and stroke events by atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA).在盎格鲁-斯堪的纳维亚心脏结局试验-降脂组（ASCOT-LLA）中，阿托伐他汀预防冠心病和中风事件的时间进程不同。

Am J Cardiol. 2005 Sep 5;96(5A):39F-44F. doi: 10.1016/j.amjcard.2005.06.025.

5

[Following the ASCOT Study. A statin for every hypertensive patient?].

MMW Fortschr Med. 2003 Apr 17;145(16):8.

6

Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): response to Server et al.阿托伐他汀对2532例2型糖尿病患者心血管事件的影响：盎格鲁-斯堪的纳维亚心脏结局试验-降脂分支（ASCOT-LLA）：对塞尔弗等人的回应

Diabetes Care. 2005 Oct;28(10):2595; author reply 2595-6. doi: 10.2337/diacare.28.10.2595.

7

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.盎格鲁-斯堪的纳维亚心脏结局试验——降脂分支（ASCOT-LLA）：一项多中心随机对照试验，阿托伐他汀对胆固醇浓度处于平均水平或低于平均水平的高血压患者冠状动脉和中风事件的预防作用。

Drugs. 2004;64 Suppl 2:43-60. doi: 10.2165/00003495-200464002-00005.

8

Atorvastatin (Lipitor).阿托伐他汀（立普妥）。

Conn Med. 1998 May;62(5):283-5.

9

Cost-effectiveness of atorvastatin for the prevention of coronary and stroke events: an economic analysis of the Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA).阿托伐他汀预防冠心病和中风事件的成本效益：盎格鲁-斯堪的纳维亚心脏结局试验——降脂分支（ASCOT-LLA）的经济学分析。

Eur J Cardiovasc Prev Rehabil. 2005 Feb;12(1):29-36.

10

The Anglo-Scandinavian Cardiac Outcomes Trial: 11-year mortality follow-up of the lipid-lowering arm in the U.K.盎格鲁-斯堪的纳维亚心脏结局试验（ASCOT）：英国降脂治疗臂 11 年死亡率随访结果

Eur Heart J. 2011 Oct;32(20):2525-32. doi: 10.1093/eurheartj/ehr333. Epub 2011 Aug 28.

引用本文的文献

1

Possible involvement of PPARγ-associated eNOS signaling activation in rosuvastatin-mediated prevention of nicotine-induced experimental vascular endothelial abnormalities.可能涉及 PPARγ 相关的 eNOS 信号激活在瑞舒伐他汀预防尼古丁诱导的实验性血管内皮异常中的作用。

Mol Cell Biochem. 2013 Feb;374(1-2):61-72. doi: 10.1007/s11010-012-1505-6. Epub 2012 Nov 10.

2

Targeting endothelial dysfunction in vascular complications associated with diabetes.针对糖尿病相关血管并发症中的内皮功能障碍

Int J Vasc Med. 2012;2012:750126. doi: 10.1155/2012/750126. Epub 2011 Oct 13.